Stephanie Gomez
@scientiststephg.bsky.social
Adoptive T cell therapies for pediatric solid tumors. Postdoc @Children’s National Hospital. PhDone! @ChiappinelliLab @GWCancer @GWSMHS @GW_IBS
https://www.linkedin.com/in/stephgomez/
https://www.linkedin.com/in/stephgomez/
Reposted by Stephanie Gomez
1. Today the NIH director issued a new directive slashing overhead rates to 15%.
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
grants.nih.gov
February 8, 2025 at 12:18 AM
1. Today the NIH director issued a new directive slashing overhead rates to 15%.
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
Reposted by Stephanie Gomez
The only possible result to this will be massive layoffs across the US higher education system
1. Today the NIH director issued a new directive slashing overhead rates to 15%.
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
I want to provide some context on what that means and why it matters.
grants.nih.gov/grants/guide...
NOT-OD-25-068: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Supplemental Guidance to the 2024 NIH Grants Policy Statement: Indirect Cost Rates NOT-OD-25-068. OD
grants.nih.gov
February 8, 2025 at 7:05 AM
The only possible result to this will be massive layoffs across the US higher education system
Reposted by Stephanie Gomez
This is... actually a fairly reasonable takeaway from this year.
December 10, 2024 at 4:25 AM
This is... actually a fairly reasonable takeaway from this year.
Reposted by Stephanie Gomez
I participated in a faculty panel a few weeks ago in which senior (ahem) faculty gave advice on careers in academia by pretending luck had very little to do with our success. One piece of advice riled me up, in which it was argued that a reason for their success was their ability to say no. 1/
December 9, 2024 at 3:16 AM
I participated in a faculty panel a few weeks ago in which senior (ahem) faculty gave advice on careers in academia by pretending luck had very little to do with our success. One piece of advice riled me up, in which it was argued that a reason for their success was their ability to say no. 1/
Reposted by Stephanie Gomez
Oh my
Musk and Ramaswamy have already identified $516B dollars in government savings — it includes cutting all of Veteran’s Affairs health care, eliminating the NIH, and ending funding for federal prisons. @morningjoe-msnbc.bsky.social
December 6, 2024 at 10:00 PM
Oh my
Reposted by Stephanie Gomez
I've decided that when researchers say a treatment is "well tolerated" it actually means "I can tolerate my patients having toxicity" and nothing to do with what the patient thinks. We can only make such a statement if we use patient-reported outcome or experience measures.
November 28, 2024 at 6:03 AM
I've decided that when researchers say a treatment is "well tolerated" it actually means "I can tolerate my patients having toxicity" and nothing to do with what the patient thinks. We can only make such a statement if we use patient-reported outcome or experience measures.
Reposted by Stephanie Gomez
Reposted by Stephanie Gomez
ICYMI - over the summer Maria Parkhurst from our branch published one of the first reports of clinical responses after adoptive cell transfer of TCR engineered private neoantigen (tumor mutation) targeting T cells in metastatic cancer patients 🧪🦠🔬🩺 1/3 #Immunosky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results - Nature Medicine
Preliminary findings in seven patients with mismatch repair-proficient metastatic colorectal cancer who were treated in the context of a phase 2 trial show that adoptive transfer of autologous periphe...
www.nature.com
November 24, 2024 at 5:02 PM
ICYMI - over the summer Maria Parkhurst from our branch published one of the first reports of clinical responses after adoptive cell transfer of TCR engineered private neoantigen (tumor mutation) targeting T cells in metastatic cancer patients 🧪🦠🔬🩺 1/3 #Immunosky
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Stephanie Gomez
UCSF hosted its first food pantry event for postdocs today, where a local food bank gives free food to UCSF employees.
This picture represents about half the line that had formed 10 minutes before the market had opened.
What the fuck are we doing here guys?
This picture represents about half the line that had formed 10 minutes before the market had opened.
What the fuck are we doing here guys?
November 21, 2024 at 2:04 AM
UCSF hosted its first food pantry event for postdocs today, where a local food bank gives free food to UCSF employees.
This picture represents about half the line that had formed 10 minutes before the market had opened.
What the fuck are we doing here guys?
This picture represents about half the line that had formed 10 minutes before the market had opened.
What the fuck are we doing here guys?
Reposted by Stephanie Gomez
Two weeks without looking/listening to any news, so much this
November 20, 2024 at 12:51 AM
Two weeks without looking/listening to any news, so much this
Reposted by Stephanie Gomez
Robert is right.
November 18, 2024 at 6:19 PM
Robert is right.
Reposted by Stephanie Gomez
There’s a clip of RFK Jr saying his first week at the NIH he’s going to tell the various institute leads that “we’re going to give drug development and infectious disease a break, a little bit of a break, for 8 years.” I cannot overstate how disastrous this would be.
November 17, 2024 at 3:27 AM
There’s a clip of RFK Jr saying his first week at the NIH he’s going to tell the various institute leads that “we’re going to give drug development and infectious disease a break, a little bit of a break, for 8 years.” I cannot overstate how disastrous this would be.
Reposted by Stephanie Gomez
Here's the #Cancer #Research #2 starter pack 🤩
Researchers, oncologists, patient advocates & more -working across all aspects of cancer research and treatment 🧪🔬⚕️
I also tried to give some exposure to #PhD #students & #postdocs - randomly picked from followers of me or my lab!
go.bsky.app/6EcjWNA
Researchers, oncologists, patient advocates & more -working across all aspects of cancer research and treatment 🧪🔬⚕️
I also tried to give some exposure to #PhD #students & #postdocs - randomly picked from followers of me or my lab!
go.bsky.app/6EcjWNA
November 17, 2024 at 6:58 PM
Reposted by Stephanie Gomez
I am excited to share our latest paper. We profiled CD8+ TILs from HPV- HNSCC patients using scRNA/TCRseq. In addition, we performed an ex vivo stimulation of cells to capture their transcriptional response. 1/n
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...
Type I Interferon Drives a Cellular State Inert to TCR‐Stimulation and Could Impede Effective T‐Cell Differentiation in Cancer
Multimodal single-cell RNA sequencing identified a population of CD8+ T cells elevated in tumor tissue enriched for interferon-stimulated genes (ISG). These ISG cells are clonally related to a popula...
onlinelibrary.wiley.com
November 17, 2024 at 12:47 PM
I am excited to share our latest paper. We profiled CD8+ TILs from HPV- HNSCC patients using scRNA/TCRseq. In addition, we performed an ex vivo stimulation of cells to capture their transcriptional response. 1/n
onlinelibrary.wiley.com/doi/10.1002/...
onlinelibrary.wiley.com/doi/10.1002/...